Application of retinoids in the treatment of renal cell carcinoma - A futile effort?

Anti-Cancer Drugs

Volumn 15, Issue 9, 2004, Pages 819-824

  Schrader, Andres J ^a,b   Von Knobloch, Rolf ^a   Heidenreich, Axel ^c   Buer, Jan ^b   Hofmann, Rainer ^a  

^a Fachbereich Medizin der Universitat Marburg   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Combined biochemotherapy; Renal cell carcinoma; Retinoic acid; Review; Systemic treatment

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; PACLITAXEL; RETINOIC ACID; RETINOID DERIVATIVE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; KIDNEY CARCINOMA; MALAISE; METASTASIS; MUCOSA; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DISEASE; SURVIVAL TIME;

ANIMALS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; KIDNEY NEOPLASMS; RETINOIDS;

EID: 8344263899     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200410000-00001     Document Type: Review

References (45)

1. Kirkali Z, Tuzel E, Mungan MU. Recent advances in kidney cancer and metastatic disease. BJU Int 2001; 88:818-824.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
3. Whelan P. The medical treatment of metastatic renal cell carcinoma. EAU Update Series 2003; 1:237-246.
4. Kirkali Z, Oebek C. Clinical aspects of renal cell carcinoma. EAU Update Series 2003; 1:189-196.
5. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000; 27:177-186.
6. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
7. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993; 11:1368-1375.
8. Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995; 76:824-832.
9. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000; 163:408-417.
10. Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22:1188-1194.
11. Heidenreich A, Schrader AJ, Varga Z. Basic science and research in renal cell carcinoma: from workbench to bedside. Curr Opin Urol 2003; 13:457-462.
12. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-193.
13. Camacho LH. Clinical applications of retinoids in cancer medicine. J Biol Regul Homeost Agents 2003; 17:98-114.
14. Warrell Jr RP, Frankel SR, Miller Jr WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324:1385-1393.
15. Hofmann WK, Ganser A, Seipelt G, Ottmann OG, Zander C, Geissler G, et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 1999; 78:125-130.
16. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990; 323:795-801.
17. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278:1073-1077.
18. Meyskens Jr FL, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, et al. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1994; 12:2060-2065.
19. Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial, Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84:328-332.
20. Culine S, Kramar A, Droz JP, Theodore C. Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol 1999; 161:173-175.
21. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84:235-241.
22. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22:235-246.
23. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19:2456-2471.
24. Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, et al. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol 2001; 19:1664-1670.
25. Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D, Murphy RF, et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol 2001; 19:2754-2763.
26. Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13:1950-1957.
27. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, et al. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996; 2:1077-1082.
28. Berg WJ, Nanus DM, Leung A, Brown KT, Hutchinson B, Mazumdar M, et al. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin Cancer Res 1999; 5:1671-1675.
29. Nanus DM, Geng Y, Shen R, Lai HK, Pfeffer SR, Pfeffer LM. Interaction of retinoic acid and interferon in renal cancer cell lines. J Interferon Cytokine Res 2000; 20:787-794.
30. Buer J, Probst M, Duensing S, Koditz H, Franzke A, Dallmann I, et al. Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. Cancer Biother Radiopharm 1997; 12:143-147.
31. Gerharz CD, Ramp U, Reinecke P, Ressler U, Dienst M, Marx N, et al. Effects of TNF-alpha and retinoic acid on the proliferation of the clear cell and chromophilic types of human renal cell carcinoma in vitro. Anticancer Res 1996; 16:1633-1641.
32. Atzpodien J, Kirchner H, Duensing S, Lopez Hanninen E, Franzke A, Buer J, et al. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid. World J Urol 1995; 13:174-177.
33. Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998; 16:1820-1825.
34. Berg WJ, Schwartz LH, Amsterdam A, Mazumdar M, Vlamis V, Law TM, et al. A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 1997; 15:353-355.
35. Wong M, Goldstein D, Woo H, Testa G, Gurney H. Alpha-interferon 2a and 1 3-cis-retinoic acid for the treatment of metastatic renal cell carcinoma. Intern Med J 2002; 32:158-162.
36. Escudier B, Ravaud A, Berton D, Chevreau C, Douillard JY, Dietrich PY. Phase II study of interferon-alpha and all-trans retinoic acid in metastatic renal cell carcinoma. J Immunother 1998; 21:62-64.
37. Jaremtchuk AV, Aman EF, Ponce W, Zarba JJ, Ferro AM, Alvarez R, et al. Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma. Am J Clin Oncol 2002; 25:123-125.
38. DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, et al. Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 1999; 17:2213-2218.
39. Zhang CC, DiPaola RS, White E, Hait WN. Restoration of taxol sensitivity in p53 mutant, bcl-2 overexpressing cell line by interferon alpha and retinoic acid. Proc Am Ass Cancer Res 1997; 38:531 (abstr 3563).
40. Vaishampayan U, Flaherty L, Du W, Hussain M. Phase II evaluation of paclitaxel, alpha-interferon, and cis-retinoic acid in advanced renal cell carcinoma. Cancer 2001; 92:519-523.
41. Goldberg JS, Vargas M, Rosmarin AS, Milowsky MI, Papanicoloau N, Gudas LJ, et al. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer 2002; 95:1220-1227.
42. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18:2972-2980.
43. Casali A, Sega FM, Casali M, Serrone L, Terzoli E. 13-cis retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma. J Exp Clin Cancer Res 1998; 17:227-229.
44. Jacobs A, Gold P, Weiden P, Aboulafia D, Rudolph R, Picozzi V, et al. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer. Cancer Invest 2000; 18:417-421.
45. Miller Jr WH, Reyno LM, Loewen GR, Huan S, Winquist E, Moore M, et al. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. Ann Oncol 2000; 11:1387-1389.